Why Cara Therapeutics Stock Is Crashing Today

Shares of Cara Therapeutics (NASDAQ: CARA) were crashing 43.9% lower as of 11:17 a.m. EDT on Thursday. The big drop came after the company announced results from its phase 2 study evaluating oral Korsuva in treating moderate-to-severe pruritis in patients with atopic dermatitis. 

With the biotech stock falling so heavily today, you'd think that all the results from the phase 2 trial were really bad. That wasn't entirely the case, though.

Image source: Getty Images.

Continue reading

Source Fool.com